BiotechTube

IMM-1-104 Monotherapy (Treatment Group A) + IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) + IMM-1-104 + modified FOLFIRINOX (Treatment Group C) + IMM-1-104 + dabrafenib (Treatment Group D) + IMM-1-104 + pembrolizumab (Treatment Group E)

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumor

Conditions

Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)

Trial Timeline

Oct 31, 2022 → Jun 1, 2027

NCT ID
NCT05585320

About IMM-1-104 Monotherapy (Treatment Group A) + IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) + IMM-1-104 + modified FOLFIRINOX (Treatment Group C) + IMM-1-104 + dabrafenib (Treatment Group D) + IMM-1-104 + pembrolizumab (Treatment Group E)

IMM-1-104 Monotherapy (Treatment Group A) + IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) + IMM-1-104 + modified FOLFIRINOX (Treatment Group C) + IMM-1-104 + dabrafenib (Treatment Group D) + IMM-1-104 + pembrolizumab (Treatment Group E) is a phase 1/2 stage product being developed by Immuneering for Advanced Solid Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT05585320. Target conditions include Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous).

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05585320Phase 1/2Active

Competing Products

20 competing products in Advanced Solid Tumor

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Immuneering

IMM-6-415Phase 1/2
33